Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 55 articles: HTML format

Single Articles

July 2022
1. ZHANG J, Li S, Zhang J, Zhang W, et al
   Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
   Cancer Lett. 2022 Jul 19:215829. doi: 10.1016/j.canlet.2022.215829.
   PubMed     Abstract available
   
   
   June 2022
2. CHUA CW, Kruithof-de Julio M
   Featuring the guest editors for the Special Issue on Prostate Cancer, Cancer Letters.
   Cancer Lett. 2022;544:215807.
   PubMed    
   
   
   
3. MAI CW, Chin KY, Foong LC, Pang KL, et al
   Modeling prostate cancer: What does it take to build an ideal tumor model?
   Cancer Lett. 2022;543:215794.
   PubMed     Abstract available
   
   
   May 2022
4. LORENZONI M, De Felice D, Beccaceci G, Di Donato G, et al
   ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3beta dependent Nkx3.1 degradation.
   Cancer Lett. 2022;534:215612.
   PubMed     Abstract available
   
   
   April 2022
5. PAPACHRISTODOULOU A, Abate-Shen C
   Precision intervention for prostate cancer: Re-evaluating who is at risk.
   Cancer Lett. 2022 Apr 28:215709. doi: 10.1016/j.canlet.2022.215709.
   PubMed     Abstract available
   
   
   March 2022
6. FONTANA F, Anselmi M, Limonta P
   Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy.
   Cancer Lett. 2022 Mar 8:215619. doi: 10.1016/j.canlet.2022.215619.
   PubMed     Abstract available
   
   
   February 2022
7. DENG W, Zhou X, Zhu K, Chen R, et al
   Novel circular RNA circ_0086722 drives tumor progression by regulating the miR-339-5p/STAT5A axis in prostate cancer.
   Cancer Lett. 2022;533:215606.
   PubMed     Abstract available
   
   
   
8. MIRO C, Di Giovanni A, Murolo M, Cicatiello AG, et al
   Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer.
   Cancer Lett. 2022 Feb 5:215581. doi: 10.1016/j.canlet.2022.215581.
   PubMed     Abstract available
   
   
   
9. LOWDER D, Rizwan K, McColl C, Paparella A, et al
   Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.
   Cancer Lett. 2022 Feb 2. pii: S0304-3835(22)00044.
   PubMed     Abstract available
   
   
   
10. CHEN H, Miao Y, Bian A, Ye J, et al
    A novel small-molecule activator of unfolded protein response suppresses castration-resistant prostate cancer growth.
    Cancer Lett. 2022;532:215580.
    PubMed     Abstract available
    
    
    January 2022
11. BAEK DS, Kim YJ, Vergara S, Conard A, et al
    A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Cancer Lett. 2022;525:97-107.
    PubMed     Abstract available
    
    
    
12. CROWLEY L, Shen MM
    Heterogeneity and complexity of the prostate epithelium: New findings from single-cell RNA sequencing studies.
    Cancer Lett. 2022;525:108-114.
    PubMed     Abstract available
    
    
    
13. CHALLASIVAKANAKA S, Vickman RE, Kakarla M, Hayward SW, et al
    Fibroblast heterogeneity in prostate carcinogenesis.
    Cancer Lett. 2022;525:76-83.
    PubMed     Abstract available
    
    
    
14. KANG J, La Manna F, Bonollo F, Sampson N, et al
    Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.
    Cancer Lett. 2022 Jan 17. pii: S0304-3835(22)00023.
    PubMed     Abstract available
    
    
    
15. QIAN C, Li D, Chen Y
    ETS factors in prostate cancer.
    Cancer Lett. 2022 Jan 13. pii: S0304-3835(22)00017.
    PubMed     Abstract available
    
    
    
16. HERNANDEZ I, Cohen M
    Linking cell-surface GRP78 to cancer: From basic research to clinical value of GRP78 antibodies.
    Cancer Lett. 2022;524:1-14.
    PubMed     Abstract available
    
    
    December 2021
17. BERNASOCCHI T, Theurillat JP
    SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
    Cancer Lett. 2021;529:11-18.
    PubMed     Abstract available
    
    
    
18. MARHOLD M, Kramer G, Krainer M, Le Magnen C, et al
    The prostate cancer landscape in Europe: Current challenges, future opportunities.
    Cancer Lett. 2021 Dec 1. pii: S0304-3835(21)00606.
    PubMed     Abstract available
    
    
    
19. CHIODELLI P, Coltrini D, Turati M, Cerasuolo M, et al
    FGFR blockade by pemigatinib treats naive and castration resistant prostate cancer.
    Cancer Lett. 2021;526:217-224.
    PubMed     Abstract available
    
    
    
20. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available
    
    
    November 2021
21. SHI M, Wang Y, Lin D, Wang Y, et al
    Patient-derived xenograft models of neuroendocrine prostate cancer.
    Cancer Lett. 2021;525:160-169.
    PubMed     Abstract available
    
    
    
22. SU S, Cao J, Meng X, Liu R, et al
    Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
    Cancer Lett. 2021 Nov 6. pii: S0304-3835(21)00558.
    PubMed     Abstract available
    
    
    
23. HAQ S, Sarodaya N, Karapurkar JK, Suresh B, et al
    CYLD destabilizes NoxO1 protein by promoting ubiquitination and regulates prostate cancer progression.
    Cancer Lett. 2021;525:146-157.
    PubMed     Abstract available
    
    
    October 2021
24. WANG C, Zhang Y, Gao WQ
    The evolving role of immune cells in prostate cancer.
    Cancer Lett. 2021 Oct 26. pii: S0304-3835(21)00545.
    PubMed     Abstract available
    
    
    
25. FLORES-TELLEZ TDNJ, Baena E
    Experimental challenges to modeling prostate cancer heterogeneity.
    Cancer Lett. 2021;524:194-205.
    PubMed     Abstract available
    
    
    
26. TOIVANEN R, Porter LH, Li Z, Clouston D, et al
    Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification.
    Cancer Lett. 2021;524:182-192.
    PubMed     Abstract available
    
    
    
27. WANG S, Chao F, Zhang C, Han D, et al
    Circular RNA circPFKP promotes cell proliferation by activating IMPDH2 in prostate cancer.
    Cancer Lett. 2021;524:109-120.
    PubMed     Abstract available
    
    
    
28. MUGONI V, Ciani Y, Nardella C, Demichelis F, et al
    Circulating RNAs in prostate cancer patients.
    Cancer Lett. 2021;524:57-69.
    PubMed     Abstract available
    
    
    
29. CACKOWSKI FC, Heath EI
    Prostate cancer dormancy and recurrence.
    Cancer Lett. 2021 Oct 5. pii: S0304-3835(21)00498.
    PubMed     Abstract available
    
    
    
30. KANAGASABAI T, Li G, Shen TH, Gladoun N, et al
    MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.
    Cancer Lett. 2021 Oct 2. pii: S0304-3835(21)00502.
    PubMed     Abstract available
    
    
    September 2021
31. TIAN P, Zhong M, Wei GH
    Mechanistic insights into genetic susceptibility to prostate cancer.
    Cancer Lett. 2021 Sep 21. pii: S0304-3835(21)00472.
    PubMed     Abstract available
    
    
    
32. RUIZ DE PORRAS V, Font A, Aytes A
    Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
    Cancer Lett. 2021 Sep 10. pii: S0304-3835(21)00430.
    PubMed     Abstract available
    
    
    August 2021
33. WANG Y, Yu J
    Dissecting multiple roles of SUMOylation in prostate cancer.
    Cancer Lett. 2021;521:88-97.
    PubMed     Abstract available
    
    
    
34. LI Q, Ye L, Zhang X, Wang M, et al
    Corrigendum to "FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling" [Cancer Lett. 402 (2017) 166-176].
    Cancer Lett. 2021 Aug 3. pii: S0304-3835(21)00383.
    PubMed    
    
    
    July 2021
35. CAMPBELL KJ, Leung HY
    Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.
    Cancer Lett. 2021 Jul 31. pii: S0304-3835(21)00378.
    PubMed     Abstract available
    
    
    
36. GAO Y, Liu Y, Liu Y, Peng Y, et al
    UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications.
    Cancer Lett. 2021;520:172-183.
    PubMed     Abstract available
    
    
    
37. LIANG J, Wang L, Poluben L, Nouri M, et al
    Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.
    Cancer Lett. 2021 Jul 10. pii: S0304-3835(21)00340.
    PubMed     Abstract available
    
    
    June 2021
38. YAMADA Y, Beltran H
    The treatment landscape of metastatic prostate cancer.
    Cancer Lett. 2021 Jun 18. pii: S0304-3835(21)00295.
    PubMed     Abstract available
    
    
    
39. JAMROZE A, Chatta G, Tang DG
    Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
    Cancer Lett. 2021;518:1-9.
    PubMed     Abstract available
    
    
    May 2021
40. HOU Z, Huang S, Li Z
    Androgens in prostate cancer: A tale that never ends.
    Cancer Lett. 2021;516:1-12.
    PubMed     Abstract available
    
    
    
41. FREELAND J, Crowell PD, Giafaglione JM, Boutros PC, et al
    Aging of the progenitor cells that initiate prostate cancer.
    Cancer Lett. 2021;515:28-35.
    PubMed     Abstract available
    
    
    
42. HUANG SB, Thapa D, Munoz AR, Hussain SS, et al
    Androgen deprivation-induced elevated nuclear SIRT1 promotes prostate tumor cell survival by reactivation of AR signaling.
    Cancer Lett. 2021;505:24-36.
    PubMed     Abstract available
    
    
    February 2021
43. LLOPIZ D, Ruiz M, Silva L, Reparaz D, et al
    Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy.
    Cancer Lett. 2021;499:279-289.
    PubMed     Abstract available
    
    
    
44. KUMAR S, Prajapati KS, Singh AK, Kushwaha PP, et al
    Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer.
    Cancer Lett. 2021 Feb 5. pii: S0304-3835(20)30637.
    PubMed     Abstract available
    
    
    January 2021
45. SONG J, Yu J, Jeong LS, Lee SK, et al
    A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells.
    Cancer Lett. 2021;497:54-65.
    PubMed     Abstract available
    
    
    
46. CHEN L, Wang YY, Li D, Wang C, et al
    LMO2 upregulation due to AR deactivation in cancer-associated fibroblasts induces non-cell-autonomous growth of prostate cancer after androgen deprivation.
    Cancer Lett. 2021 Jan 24. pii: S0304-3835(21)00034.
    PubMed     Abstract available
    
    
    November 2020
47. LEECH M, Osman S, Jain S, Marignol L, et al
    Mini review: Personalization of the radiation therapy management of prostate cancer using MRI-based radiomics.
    Cancer Lett. 2020 Nov 4. pii: S0304-3835(20)30565.
    PubMed     Abstract available
    
    
    September 2020
48. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
    Cancer Lett. 2020 Sep 12. pii: S0304-3835(20)30472.
    PubMed     Abstract available
    
    
    August 2020
49. WANG J, Xu W, Wang B, Lin G, et al
    GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers.
    Cancer Lett. 2020;485:45-55.
    PubMed     Abstract available
    
    
    
50. CHEN D, Chou FJ, Chen Y, Tian H, et al
    Targeting the radiation-induced TR4 nuclear receptor-mediated QKI/circZEB1/miR-141-3p/ZEB1 signaling increases prostate cancer radiosensitivity.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30396.
    PubMed     Abstract available
    
    
    July 2020
51. BATES M, Boland A, McDermott N, Marignol L, et al
    YB-1: The key to personalised prostate cancer management?
    Cancer Lett. 2020 Jul 15. pii: S0304-3835(20)30361.
    PubMed     Abstract available
    
    
    June 2020
52. ZHANG M, Wang Y, Matyunina LV, Akbar A, et al
    The ability of miRNAs to induce mesenchymal-to-epithelial transition (MET) in cancer cells is highly dependent upon genetic background.
    Cancer Lett. 2020;480:15-23.
    PubMed     Abstract available
    
    
    May 2020
53. WANG S, Gilbreath C, Kollipara RK, Sonavane R, et al
    Mithramycin suppresses DNA damage repair via targeting androgen receptor in prostate cancer.
    Cancer Lett. 2020 May 30. pii: S0304-3835(20)30289.
    PubMed     Abstract available
    
    
    
54. MIRANDA-GONCALVES V, Lameirinhas A, Henrique R, Baltazar F, et al
    The metabolic landscape of urological cancers: New therapeutic perspectives.
    Cancer Lett. 2020;477:76-87.
    PubMed     Abstract available
    
    
    April 2020
55. SIDDIQUI S, Libertini SJ, Lucas CA, Lombard AP, et al
    The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells.
    Cancer Lett. 2020 Apr 21. pii: S0304-3835(20)30163.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: